$CPMV
Mosaic ImmunoEngineering Inc.

2023 Q4 Form 10-Q Financial Statement

#000168316823007588 Filed on November 02, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $225.6K $226.9K
YoY Change -22.34% -25.87%
% of Gross Profit
Research & Development $49.99K $84.93K
YoY Change -75.85% -59.77%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $275.6K $311.9K
YoY Change -44.6% -39.7%
Operating Profit -$311.9K
YoY Change -39.7%
Interest Expense -$19.94K -$21.37K
YoY Change -45.44% -105.88%
% of Operating Profit
Other Income/Expense, Net $0.00 -$21.38K
YoY Change -105.88%
Pretax Income -$295.6K -$333.2K
YoY Change -44.66% 116.89%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$295.6K -$333.2K
YoY Change -44.66% 116.88%
Net Earnings / Revenue
Basic Earnings Per Share -$0.05
Diluted Earnings Per Share -$0.04 -$0.05
COMMON SHARES
Basic Shares Outstanding 7.242M shares 7.242M shares
Diluted Shares Outstanding 7.236M shares

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $156.2K $252.9K
YoY Change -29.22% -34.16%
Cash & Equivalents $156.2K $252.9K
Short-Term Investments
Other Short-Term Assets $23.36K $32.63K
YoY Change -42.51% -33.12%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $179.5K $285.5K
YoY Change -31.29% -34.05%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $179.5K $285.5K
Total Long-Term Assets $0.00 $0.00
Total Assets $179.5K $285.5K
YoY Change -31.29% -34.05%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $118.5K $116.4K
YoY Change -11.23% -4.01%
Accrued Expenses $641.8K $649.2K
YoY Change 9.74% 12.73%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.733M $4.569M
YoY Change 20.81% 26.99%
LONG-TERM LIABILITIES
Long-Term Debt $1.318M $1.298M
YoY Change 7.26% 8.84%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $1.318M $1.298M
YoY Change 7.26% 8.84%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.733M $4.569M
Total Long-Term Liabilities $1.318M $1.298M
Total Liabilities $6.051M $5.867M
YoY Change 17.58% 22.47%
SHAREHOLDERS EQUITY
Retained Earnings -$7.916M -$7.621M
YoY Change 14.59% 19.56%
Common Stock $72.00 $72.00
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$5.871M -$5.581M
YoY Change
Total Liabilities & Shareholders Equity $179.5K $285.5K
YoY Change -31.29% -34.05%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$295.6K -$333.2K
YoY Change -44.66% 116.88%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$96.72K -$110.1K
YoY Change -40.84% -33.23%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities $0.00 $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -96.72K -110.1K
Cash From Investing Activities 0.000 0.000
Cash From Financing Activities 0.000 0.000
Net Change In Cash -96.72K -110.1K
YoY Change -40.84% -161.79%
FREE CASH FLOW
Cash From Operating Activities -$96.72K -$110.1K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity File Number
EntityFileNumber
000-22182
dei Entity Registrant Name
EntityRegistrantName
MOSAIC IMMUNOENGINEERING, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-1070278
dei Entity Address Address Line1
EntityAddressAddressLine1
9114 Adams Ave., #202
dei Entity Address City Or Town
EntityAddressCityOrTown
Huntington Beach
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Central Index Key
EntityCentralIndexKey
0000836564
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92646
dei City Area Code
CityAreaCode
657
dei Local Phone Number
LocalPhoneNumber
208-0890
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
7242137 shares
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
252898 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
220645 usd
CY2023Q3 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
32630 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
40632 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
285528 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
261277 usd
CY2023Q3 us-gaap Assets
Assets
285528 usd
CY2022Q4 us-gaap Assets
Assets
261277 usd
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
116421 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
133464 usd
CY2023Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
0 usd
CY2022Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
46700 usd
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2993793 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2399132 usd
CY2023Q3 CPMV Accrued Consulting
AccruedConsulting
809528 usd
CY2022Q4 CPMV Accrued Consulting
AccruedConsulting
753570 usd
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
649225 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
584808 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
4568967 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3917674 usd
CY2023Q3 us-gaap Convertible Debt
ConvertibleDebt
1297590 usd
CY2022Q4 us-gaap Convertible Debt
ConvertibleDebt
1228361 usd
CY2023Q3 us-gaap Liabilities
Liabilities
5866557 usd
CY2022Q4 us-gaap Liabilities
Liabilities
5146035 usd
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7242137 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7242137 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7242137 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7242137 shares
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
72 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
72 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2039677 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2023271 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-7620779 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-6908102 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-5581029 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-4884758 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
285528 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
261277 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
84927 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
211082 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
385460 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
841435 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
226944 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
306124 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
738690 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1288533 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
311871 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
517206 usd
us-gaap Operating Expenses
OperatingExpenses
1124150 usd
us-gaap Operating Expenses
OperatingExpenses
2129968 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-311871 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-517206 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-1124150 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-2129968 usd
CY2023Q3 CPMV Gain On Redemption Of Preferred Stock Of Holocom
GainOnRedemptionOfPreferredStockOfHolocom
0 usd
CY2022Q3 CPMV Gain On Redemption Of Preferred Stock Of Holocom
GainOnRedemptionOfPreferredStockOfHolocom
343000 usd
CPMV Gain On Redemption Of Preferred Stock Of Holocom
GainOnRedemptionOfPreferredStockOfHolocom
433000 usd
CPMV Gain On Redemption Of Preferred Stock Of Holocom
GainOnRedemptionOfPreferredStockOfHolocom
343000 usd
CY2023Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
16 usd
CY2022Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
11 usd
us-gaap Interest And Other Income
InterestAndOtherIncome
3402 usd
us-gaap Interest And Other Income
InterestAndOtherIncome
25 usd
CY2023Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0 usd
CY2022Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
56700 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
46700 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
58000 usd
CY2023Q3 us-gaap Noninterest Expense
NoninterestExpense
18484 usd
CY2022Q3 us-gaap Noninterest Expense
NoninterestExpense
18484 usd
us-gaap Noninterest Expense
NoninterestExpense
54849 usd
us-gaap Noninterest Expense
NoninterestExpense
51254 usd
CY2023Q3 us-gaap Accretion Expense
AccretionExpense
2907 usd
CY2022Q3 us-gaap Accretion Expense
AccretionExpense
17673 usd
us-gaap Accretion Expense
AccretionExpense
14380 usd
us-gaap Accretion Expense
AccretionExpense
64171 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-21375 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
363554 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
413873 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
285600 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-333246 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-153652 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-710277 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1844368 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2400 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2400 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-333246 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-153652 usd
us-gaap Net Income Loss
NetIncomeLoss
-712677 usd
us-gaap Net Income Loss
NetIncomeLoss
-1846768 usd
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.05
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.05
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.10
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.10
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.26
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.26
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7236447 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7236447 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7235447 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7235447 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7236447 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7236447 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7235447 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7235447 shares
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-5253312 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5529 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-333246 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-5581029 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-4255125 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
51592 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-153652 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-4357185 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-4884758 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
16406 usd
us-gaap Net Income Loss
NetIncomeLoss
-712677 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-5581029 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-2799011 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
288594 usd
us-gaap Net Income Loss
NetIncomeLoss
-1846768 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-4357185 usd
us-gaap Net Income Loss
NetIncomeLoss
-712677 usd
us-gaap Net Income Loss
NetIncomeLoss
-1846768 usd
CPMV Gain On Redemption Of Preferred Stock Of Holocom
GainOnRedemptionOfPreferredStockOfHolocom
433000 usd
CPMV Gain On Redemption Of Preferred Stock Of Holocom
GainOnRedemptionOfPreferredStockOfHolocom
343000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
16406 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
288594 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
46700 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
58000 usd
us-gaap Noninterest Expense
NoninterestExpense
54849 usd
us-gaap Noninterest Expense
NoninterestExpense
51254 usd
us-gaap Accretion Expense
AccretionExpense
14380 usd
us-gaap Accretion Expense
AccretionExpense
64171 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-8002 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
5438 usd
us-gaap Increase Decrease In Other Accounts Payable
IncreaseDecreaseInOtherAccountsPayable
-17043 usd
us-gaap Increase Decrease In Other Accounts Payable
IncreaseDecreaseInOtherAccountsPayable
7770 usd
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
594661 usd
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
753932 usd
CPMV Increase Decrease In Accrued Consulting
IncreaseDecreaseInAccruedConsulting
55958 usd
CPMV Increase Decrease In Accrued Consulting
IncreaseDecreaseInAccruedConsulting
234900 usd
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
64417 usd
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
325948 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-400747 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-526637 usd
CPMV Proceeds From Redemption Of Preferred Stock Of Holocom
ProceedsFromRedemptionOfPreferredStockOfHolocom
433000 usd
CPMV Proceeds From Redemption Of Preferred Stock Of Holocom
ProceedsFromRedemptionOfPreferredStockOfHolocom
343000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
433000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
343000 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
341632 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
341632 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
32253 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
157995 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
220645 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
226142 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
252898 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
384137 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
2400 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
2400 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Nature Of Operations
NatureOfOperations
<p id="xdx_805_eus-gaap--NatureOfOperations_zNrhUvfFejHh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="display: inline-block; width: 0.5in; float: left; white-space: nowrap">1.</span> <span id="xdx_823_z4aawKR2kEb8">Organization and Business</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Organization</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mosaic ImmunoEngineering, Inc. (the “Company,” “Mosaic,” “we,” “us,” or “our”), formerly known as Patriot Scientific Corporation, is a corporation organized under Delaware law on March 24, 1992. We are a development-stage biotechnology company focused on advancing and eventually commercializing our proprietary immunotherapy platform technology. Our lead immunotherapy product candidate, MIE-101, is based on a naturally occurring plant virus known as Cowpea mosaic virus (or CPMV) which is believed to be non-infectious in humans and animals. However, because of its virus structure and genetic composition, CPMV elicits a strong immune response when delivered directly into tumors as shown in our preclinical studies. Data from numerous mouse cancer models and in companion dogs with naturally occurring tumors show the ability of intratumoral (“IT”) administration of CPMV to result in anti-tumor effects in treated tumors and systemically at other sites of disease through immune activation. MIE-101 is currently in late-stage preclinical development and our goal is to advance MIE-101 into veterinary studies and into Phase I clinical trials within 18 to 24 months from the date we are able to raise sufficient funding.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has two inactive wholly owned subsidiaries: Mosaic ImmunoEngineering Development Company, a corporation organized under Delaware law on March 30, 2020 and Patriot Data Solutions Group, Inc.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Going Concern and Management’s Plans</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying unaudited condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. At September 30, 2023, the Company had cash and cash equivalents of $<span id="xdx_905_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0p0_c20230930_zZJQ7xBa4GFb" title="Cash and cash equivalents">252,898</span> and has not yet generated any revenues. Therefore, our ability to continue our operations is highly dependent on our ability to raise capital to fund future operations. We anticipate, based on currently proposed plans and assumptions that our cash and cash equivalents on hand will not satisfy our operational and capital requirements through twelve months from the filing date of this Quarterly Report on Form 10-Q.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are a number of uncertainties associated with our ability to raise additional capital and we have no current arrangements with respect to any additional financing. Consequently, there can be no assurance that any additional financing on commercially reasonable terms, or at all, will be available when needed. The inability to obtain additional capital will delay our ability to conduct our business operations and may require us to cease our operations altogether. In addition, any additional equity financing may involve substantial dilution to our then existing stockholders. The above matters raise substantial doubt regarding our ability to continue as a going concern.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
252898 usd
CY2023Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
252898 usd
CY2022Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
220645 usd
CY2022Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
46700 usd
CY2022Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
46700 usd
CY2022Q4 CPMV Accrued Patent Expenses
AccruedPatentExpenses
382207 usd
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
51837 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
25357 usd
CY2023Q3 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Contingent Liability
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability
177244 usd
CY2022Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Contingent Liability
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability
177244 usd
CY2023Q3 CPMV Accrued Patent Expenses
AccruedPatentExpenses
420144 usd
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
649225 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
584808 usd
CY2023Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
0 usd
CY2023Q3 CPMV Convertible Notes Redemption Value
ConvertibleNotesRedemptionValue
1145790 usd
CY2023Q3 us-gaap Share Based Compensation
ShareBasedCompensation
5529 usd
CY2022Q3 us-gaap Share Based Compensation
ShareBasedCompensation
51592 usd
us-gaap Share Based Compensation
ShareBasedCompensation
16406 usd
us-gaap Share Based Compensation
ShareBasedCompensation
288594 usd
CY2023Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
0 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
0 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
0 usd
CY2022Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
0 usd

Files In Submission

Name View Source Status
0001683168-23-007588-index-headers.html Edgar Link pending
0001683168-23-007588-index.html Edgar Link pending
0001683168-23-007588.txt Edgar Link pending
0001683168-23-007588-xbrl.zip Edgar Link pending
cpmv-20230930.xsd Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
mosaic_ex3101.htm Edgar Link pending
mosaic_ex3102.htm Edgar Link pending
mosaic_ex3201.htm Edgar Link pending
mosaic_ex3202.htm Edgar Link pending
mosaic_i10q-093023.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
cpmv-20230930_pre.xml Edgar Link unprocessable
cpmv-20230930_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
mosaic_i10q-093023_htm.xml Edgar Link completed
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
cpmv-20230930_def.xml Edgar Link unprocessable
cpmv-20230930_cal.xml Edgar Link unprocessable